Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.
Eureka Therapeutics is a clinical-stage biopharmaceutical company in Emeryville, California, developing next-generation T-cell therapies for cancer, with a focus on hard-to-treat solid tumors. Founded in 2006 by Dr. Cheng Liu, the company pairs its E-ALPHA phage-display antibody engine with its ARTEMIS T-cell receptor platform - an alternative to conventional CAR-T designed to keep engineered T cells potent inside immunosuppressive tumors while sharply reducing the inflammatory cytokine release linked to CAR-T toxicity. Its lead program, ECT204, targets GPC3-positive advanced liver cancer and has received FDA RMAT designation.
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class oral small-molecule multi-kinase inhibitor that co-targets casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7/CDK9) - three master regulators of cancer cell survival and transcription. Founded by veteran biotech executive David N. Cook and emerging from stealth in March 2024 with $20M in Series A financing from Alta Partners, the company is advancing BTX-A51 through Phase 2a trials in relapsed/refractory acute myeloid leukemia and genetically-defined (GATA3-mutant) ER+/HER2- metastatic breast cancer.
Samuel Murphy is co-founder and CEO of Salubris Biotherapeutics, a clinical-stage biotech in Gaithersburg, Maryland developing complex biologics for cardiovascular, oncology, and neurodegenerative disease. A Penn-trained virologist who did his postdoc in the lab that became Spark Therapeutics, he spent a decade in pharma strategy consulting and life-sciences investment banking before joining Salubris in 2017 and taking the CEO seat in 2020. His lead program, JK07, is the first clinical-stage selective ErbB4 agonist aimed at being a disease-modifying biologic for heart failure. He also runs international business development for the company's Chinese parent, Shenzhen Salubris Pharmaceuticals.